Backgrounds Distal pancreatectomy with en bloc celiac axis resection (DP-CAR) is an
extended surgical procedure for patients with locally advanced cancer of the pancreatic …

Pancreatic ductal adenocarcinoma (PDAC) is highly malignant. While cancers in other
organs have shown clear improvements in 5‐year survival, the 5‐year survival rate of …

Pancreatic cancer has traditionally been associated with a dismal prognosis, even in early
stages of the disease. In recent years, the introduction of newer generation chemotherapy …

Introduction Cancer immunotherapy represents one of the most important innovations in
modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent …

Background The added value of radiotherapy following neoadjuvant FOLFIRINOX
chemotherapy in patients with resectable or borderline resectable pancreatic cancer ((B) …

Pancreatic cancer is one of the most lethal of all malignancies. One of the reasons for the
dismal prognosis is that most diagnoses are made when the disease is either locally …

Objective: By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the
clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in …

Background For patients with pancreatic ductal adenocarcinoma (PDAC), surgical resection
remains the only potentially curative treatment. Surgery is generally followed by …

To evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NG) as a first-line
treatment for advanced pancreatic cancer. A meta-analysis was performed to assess the …

Background There is no agreed upon standard of care for borderline‐resectable pancreatic
cancer (BRPC) or locally‐advanced pancreatic cancer (LAPC) patients regarding the benefit …